Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratoire de Génétique Moléculaire Institut de Recherche Necker Enfants Malades, |
RCV000782149 | SCV000920613 | likely pathogenic | Epileptic encephalopathy | 2019-03-01 | criteria provided, single submitter | clinical testing | |
Centre de Biologie Pathologie Génétique, |
RCV002274100 | SCV002558979 | pathogenic | Neurodevelopmental delay | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV005056544 | SCV005697591 | likely pathogenic | Developmental and epileptic encephalopathy, 26 | 2024-03-15 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 323 of the KCNB1 protein (p.Thr323Ile). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with developmental and epileptic encephalopathy (PMID: 31513310). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 633622). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNB1 protein function with a positive predictive value of 80%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |